Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 70

1.

Discovery of Furanone-Based Radiopharmaceuticals for Diagnostic Targeting of COX-1 in Ovarian Cancer.

Uddin MJ, Wilson AJ, Crews BC, Malerba P, Uddin MI, Kingsley PJ, Ghebreselasie K, Daniel CK, Nickels ML, Tantawy MN, Jashim E, Manning HC, Khabele D, Marnett LJ.

ACS Omega. 2019 May 31;4(5):9251-9261. doi: 10.1021/acsomega.9b01093. Epub 2019 May 24.

2.

Prostaglandin E2 glyceryl ester is an endogenous agonist of the nucleotide receptor P2Y6.

Brüser A, Zimmermann A, Crews BC, Sliwoski G, Meiler J, König GM, Kostenis E, Lede V, Marnett LJ, Schöneberg T.

Sci Rep. 2017 May 24;7(1):2380. doi: 10.1038/s41598-017-02414-8.

3.

Inhibition of the Biosynthesis of Prostaglandin E2 By Low-Dose Aspirin: Implications for Adenocarcinoma Metastasis.

Boutaud O, Sosa IR, Amin T, Oram D, Adler D, Hwang HS, Crews BC, Milne G, Harris BK, Hoeksema M, Knollmann BC, Lammers PE, Marnett LJ, Massion PP, Oates JA.

Cancer Prev Res (Phila). 2016 Nov;9(11):855-865. Epub 2016 Aug 23.

4.

Fluorocoxib A enables targeted detection of cyclooxygenase-2 in laser-induced choroidal neovascularization.

Uddin MJ, Moore CE, Crews BC, Daniel CK, Ghebreselasie K, McIntyre JO, Marnett LJ, Jayagopal A.

J Biomed Opt. 2016 Sep 1;21(9):90503. doi: 10.1117/1.JBO.21.9.090503.

5.

Antitumor Activity of Cytotoxic Cyclooxygenase-2 Inhibitors.

Uddin MJ, Crews BC, Xu S, Ghebreselasie K, Daniel CK, Kingsley PJ, Banerjee S, Marnett LJ.

ACS Chem Biol. 2016 Nov 18;11(11):3052-3060. Epub 2016 Sep 19.

6.

Fluorocoxib A loaded nanoparticles enable targeted visualization of cyclooxygenase-2 in inflammation and cancer.

Uddin MJ, Werfel TA, Crews BC, Gupta MK, Kavanaugh TE, Kingsley PJ, Boyd K, Marnett LJ, Duvall CL.

Biomaterials. 2016 Jun;92:71-80. doi: 10.1016/j.biomaterials.2016.03.028. Epub 2016 Mar 21.

7.

nido-Dicarbaborate Induces Potent and Selective Inhibition of Cyclooxygenase-2.

Neumann W, Xu S, Sárosi MB, Scholz MS, Crews BC, Ghebreselasie K, Banerjee S, Marnett LJ, Hey-Hawkins E.

ChemMedChem. 2016 Jan 19;11(2):175-8. doi: 10.1002/cmdc.201500199. Epub 2015 Jun 18.

8.

Targeted imaging of cancer by fluorocoxib C, a near-infrared cyclooxygenase-2 probe.

Uddin MJ, Crews BC, Ghebreselasie K, Daniel CK, Kingsley PJ, Xu S, Marnett LJ.

J Biomed Opt. 2015 May;20(5):50502. doi: 10.1117/1.JBO.20.5.050502.

9.

Design of Fluorine-Containing 3,4-Diarylfuran-2(5H)-ones as Selective COX-1 Inhibitors.

Uddin MJ, Elleman AV, Ghebreselasie K, Daniel CK, Crews BC, Nance KD, Huda T, Marnett LJ.

ACS Med Chem Lett. 2014 Oct 12;5(11):1254-8. doi: 10.1021/ml500344j. eCollection 2014 Nov 13.

10.

Conjugation of cisplatin analogues and cyclooxygenase inhibitors to overcome cisplatin resistance.

Neumann W, Crews BC, Sárosi MB, Daniel CM, Ghebreselasie K, Scholz MS, Marnett LJ, Hey-Hawkins E.

ChemMedChem. 2015 Jan;10(1):183-92. doi: 10.1002/cmdc.201402353. Epub 2014 Oct 15.

11.

Trifluoromethyl fluorocoxib a detects cyclooxygenase-2 expression in inflammatory tissues and human tumor xenografts.

Uddin MJ, Crews BC, Huda I, Ghebreselasie K, Daniel CK, Marnett LJ.

ACS Med Chem Lett. 2014 Jan 23;5(4):446-50. doi: 10.1021/ml400485g. eCollection 2014 Apr 10.

12.

PET radiotracer [¹⁸F]-P6 selectively targeting COX-1 as a novel biomarker in ovarian cancer: preliminary investigation.

Perrone MG, Malerba P, Uddin J, Vitale P, Panella A, Crews BC, Daniel CK, Ghebreselasie K, Nickels M, Tantawy MN, Manning HC, Marnett LJ, Scilimati A.

Eur J Med Chem. 2014 Jun 10;80:562-568. doi: 10.1016/j.ejmech.2014.04.074. Epub 2014 Apr 29.

13.

Conjugates of cisplatin and cyclooxygenase inhibitors as potent antitumor agents overcoming cisplatin resistance.

Neumann W, Crews BC, Marnett LJ, Hey-Hawkins E.

ChemMedChem. 2014 Jun;9(6):1150-3. doi: 10.1002/cmdc.201402074. Epub 2014 May 6.

14.

The 2'-Trifluoromethyl Analogue of Indomethacin Is a Potent and Selective COX-2 Inhibitor.

Blobaum AL, Uddin MJ, Felts AS, Crews BC, Rouzer CA, Marnett LJ.

ACS Med Chem Lett. 2013 May 9;4(5):486-490. Epub 2013 Mar 25.

15.

Design, synthesis, and structure-activity relationship studies of fluorescent inhibitors of cycloxygenase-2 as targeted optical imaging agents.

Uddin MJ, Crews BC, Ghebreselasie K, Marnett LJ.

Bioconjug Chem. 2013 Apr 17;24(4):712-23. doi: 10.1021/bc300693w. Epub 2013 Mar 28.

16.

Convergent synthesis and evaluation of (18)F-labeled azulenic COX2 probes for cancer imaging.

Nolting DD, Nickels M, Tantawy MN, Yu JY, Xie J, Peterson TE, Crews BC, Marnett L, Gore JC, Pham W.

Front Oncol. 2013 Jan 3;2:207. doi: 10.3389/fonc.2012.00207. eCollection 2012.

17.

Substrate-Selective Inhibition of Cyclooxygenase-2: Development and Evaluation of Achiral Profen Probes.

Windsor MA, Hermanson DJ, Kingsley PJ, Xu S, Crews BC, Ho W, Keenan CM, Banerjee S, Sharkey KA, Marnett LJ.

ACS Med Chem Lett. 2012 Sep 13;3(9):759-763. Epub 2012 Aug 15.

18.

Seeing it through: translational validation of new medical imaging modalities.

Aldrich MB, Marshall MV, Sevick-Muraca EM, Lanza G, Kotyk J, Culver J, Wang LV, Uddin J, Crews BC, Marnett LJ, Liao JC, Contag C, Crawford JM, Wang K, Reisdorph B, Appelman H, Turgeon DK, Meyer C, Wang T.

Biomed Opt Express. 2012 Apr 1;3(4):764-76. doi: 10.1364/BOE.3.000764. Epub 2012 Mar 22.

19.

Cyclooxygenase-1-selective inhibitors based on the (E)-2'-des-methyl-sulindac sulfide scaffold.

Liedtke AJ, Crews BC, Daniel CM, Blobaum AL, Kingsley PJ, Ghebreselasie K, Marnett LJ.

J Med Chem. 2012 Mar 8;55(5):2287-300. doi: 10.1021/jm201528b. Epub 2012 Feb 14.

20.

Total Synthesis (+)-7-Bromotrypargine and Unnatural Analogs: Biological Evaluation Uncovers Activity at CNS Targets of Therapeutic Relevance.

Brogan JT, Stoops SL, Crews BC, Marnett LJ, Lindsley CW.

ACS Chem Neurosci. 2011 Nov 16;2(11):633-639.

21.

Fluorinated COX-2 inhibitors as agents in PET imaging of inflammation and cancer.

Uddin MJ, Crews BC, Ghebreselasie K, Huda I, Kingsley PJ, Ansari MS, Tantawy MN, Reese J, Marnett LJ.

Cancer Prev Res (Phila). 2011 Oct;4(10):1536-45. doi: 10.1158/1940-6207.CAPR-11-0120. Epub 2011 Sep 7.

22.

[I]-Celecoxib Analogues as SPECT Tracers of Cyclooxygenase-2 in Inflammation.

Uddin MJ, Crews BC, Ghebreselasie K, Tantawy MN, Marnett LJ.

ACS Med Chem Lett. 2011 Feb 10;2(2):160-164. Epub 2010 Nov 12.

23.

Total synthesis and biological evaluation of tambjamine K and a library of unnatural analogs.

Aldrich LN, Stoops SL, Crews BC, Marnett LJ, Lindsley CW.

Bioorg Med Chem Lett. 2010 Sep 1;20(17):5207-11. doi: 10.1016/j.bmcl.2010.06.154. Epub 2010 Jul 23.

PMID:
20655217
24.

Light-induced isomerization of apoptolidin a leads to inversion of C2-C3 double bond geometry.

Bachmann BO, McNees R, Melancon BJ, Ghidu VP, Clark R, Crews BC, Deguire SM, Marnett LJ, Sulikowski GA.

Org Lett. 2010 Jul 2;12(13):2944-7. doi: 10.1021/ol1009398.

25.

Selective visualization of cyclooxygenase-2 in inflammation and cancer by targeted fluorescent imaging agents.

Uddin MJ, Crews BC, Blobaum AL, Kingsley PJ, Gorden DL, McIntyre JO, Matrisian LM, Subbaramaiah K, Dannenberg AJ, Piston DW, Marnett LJ.

Cancer Res. 2010 May 1;70(9):3618-27. doi: 10.1158/0008-5472.CAN-09-2664.

26.

Structural determinants for calcium mobilization by prostaglandin E2 and prostaglandin F2alpha glyceryl esters in RAW 264.7 cells and H1819 cells.

Richie-Jannetta R, Nirodi CS, Crews BC, Woodward DF, Wang JW, Duff PT, Marnett LJ.

Prostaglandins Other Lipid Mediat. 2010 Jun;92(1-4):19-24. doi: 10.1016/j.prostaglandins.2010.01.003. Epub 2010 Feb 10.

27.

Podophyllotoxin analogues active versus Trypanosoma brucei.

Uddin MJ, Smithson DC, Brown KM, Crews BC, Connelly M, Zhu F, Marnett LJ, Guy RK.

Bioorg Med Chem Lett. 2010 Mar 1;20(5):1787-91. doi: 10.1016/j.bmcl.2010.01.009. Epub 2010 Jan 11.

28.

Progress toward the total synthesis of lucentamycin A: total synthesis and biological evaluation of 8-epi-lucentamycin A.

Daniels RN, Melancon BJ, Wang EA, Crews BC, Marnett LJ, Sulikowski GA, Lindsley CW.

J Org Chem. 2009 Nov 20;74(22):8852-5. doi: 10.1021/jo902115s.

PMID:
19908916
29.

Desmethyl derivatives of indomethacin and sulindac as probes for cyclooxygenase-dependent biology.

Felts AS, Ji C, Stafford JB, Crews BC, Kingsley PJ, Rouzer CA, Washington MK, Subbaramaiah K, Siegel BS, Young SM, Dannenberg AJ, Marnett LJ.

ACS Chem Biol. 2007 Jul 20;2(7):479-83. Epub 2007 Jun 29.

PMID:
17602619
30.

Metabolism in vitro and in vivo of the DNA base adduct, M1G.

Knutson CG, Akingbade D, Crews BC, Voehler M, Stec DF, Marnett LJ.

Chem Res Toxicol. 2007 Mar;20(3):550-7. Epub 2007 Feb 21.

PMID:
17311424
31.

In vivo oxidative metabolism of a major peroxidation-derived DNA adduct, M1dG.

Otteneder MB, Knutson CG, Daniels JS, Hashim M, Crews BC, Remmel RP, Wang H, Rizzo C, Marnett LJ.

Proc Natl Acad Sci U S A. 2006 Apr 25;103(17):6665-9. Epub 2006 Apr 13.

32.

Indolyl esters and amides related to indomethacin are selective COX-2 inhibitors.

Kalgutkar AS, Crews BC, Saleh S, Prudhomme D, Marnett LJ.

Bioorg Med Chem. 2005 Dec 15;13(24):6810-22. Epub 2005 Sep 19.

PMID:
16169736
33.

Inhibition of cyclooxygenase with indomethacin phenethylamide reduces atherosclerosis in apoE-null mice.

Burleigh ME, Babaev VR, Patel MB, Crews BC, Remmel RP, Morrow JD, Oates JA, Marnett LJ, Fazio S, Linton MF.

Biochem Pharmacol. 2005 Aug 1;70(3):334-42.

PMID:
15950196
34.

The glyceryl ester of prostaglandin E2 mobilizes calcium and activates signal transduction in RAW264.7 cells.

Nirodi CS, Crews BC, Kozak KR, Morrow JD, Marnett LJ.

Proc Natl Acad Sci U S A. 2004 Feb 17;101(7):1840-5. Epub 2004 Feb 6.

35.

Studies on the metabolism of the novel, selective cyclooxygenase-2 inhibitor indomethacin phenethylamide in rat, mouse, and human liver microsomes: identification of active metabolites.

Remmel RP, Crews BC, Kozak KR, Kalgutkar AS, Marnett LJ.

Drug Metab Dispos. 2004 Jan;32(1):113-22. Erratum in: Drug Metab Dispos. 2004 Mar;32(3):366. Algutkar, Amit S [corrected to Kalgutkar, Amit S].

PMID:
14709628
36.

Metabolism of the endocannabinoids, 2-arachidonylglycerol and anandamide, into prostaglandin, thromboxane, and prostacyclin glycerol esters and ethanolamides.

Kozak KR, Crews BC, Morrow JD, Wang LH, Ma YH, Weinander R, Jakobsson PJ, Marnett LJ.

J Biol Chem. 2002 Nov 22;277(47):44877-85. Epub 2002 Sep 19.

37.

Amide derivatives of meclofenamic acid as selective cyclooxygenase-2 inhibitors.

Kalgutkar AS, Rowlinson SW, Crews BC, Marnett LJ.

Bioorg Med Chem Lett. 2002 Feb 25;12(4):521-4.

PMID:
11844663
38.

Metabolism of prostaglandin glycerol esters and prostaglandin ethanolamides in vitro and in vivo.

Kozak KR, Crews BC, Ray JL, Tai HH, Morrow JD, Marnett LJ.

J Biol Chem. 2001 Oct 5;276(40):36993-8. Epub 2001 Jul 10.

39.

Characterization of the lysyl adducts of prostaglandin H-synthases that are derived from oxygenation of arachidonic acid.

Boutaud O, Brame CJ, Chaurand P, Li J, Rowlinson SW, Crews BC, Ji C, Marnett LJ, Caprioli RM, Roberts LJ 2nd, Oates JA.

Biochemistry. 2001 Jun 12;40(23):6948-55.

PMID:
11389610
40.

Catalytic consumption of nitric oxide by prostaglandin H synthase-1 regulates platelet function.

O'Donnell VB, Coles B, Lewis MJ, Crews BC, Marnett LJ, Freeman BA.

J Biol Chem. 2000 Dec 8;275(49):38239-44.

41.

Ester and amide derivatives of the nonsteroidal antiinflammatory drug, indomethacin, as selective cyclooxygenase-2 inhibitors.

Kalgutkar AS, Marnett AB, Crews BC, Remmel RP, Marnett LJ.

J Med Chem. 2000 Jul 27;43(15):2860-70.

PMID:
10956194
42.

Regulation of prostaglandin biosynthesis by nitric oxide is revealed by targeted deletion of inducible nitric-oxide synthase.

Marnett LJ, Wright TL, Crews BC, Tannenbaum SR, Morrow JD.

J Biol Chem. 2000 May 5;275(18):13427-30.

43.
44.

Discovery of a new class of selective cyclooxygenase-2 (COX-2) inhibitor that covalently modifies the isozyme.

Kalgutkar AS, Crews BC, Rowlinson SW, Garner C, Marnett LJ.

Adv Exp Med Biol. 1999;469:139-43. No abstract available.

PMID:
10667322
45.

Biochemically based design of cyclooxygenase-2 (COX-2) inhibitors: facile conversion of nonsteroidal antiinflammatory drugs to potent and highly selective COX-2 inhibitors.

Kalgutkar AS, Crews BC, Rowlinson SW, Marnett AB, Kozak KR, Remmel RP, Marnett LJ.

Proc Natl Acad Sci U S A. 2000 Jan 18;97(2):925-30.

46.

Elevated CSF prostaglandin E2 levels in patients with probable AD.

Montine TJ, Sidell KR, Crews BC, Markesbery WR, Marnett LJ, Roberts LJ 2nd, Morrow JD.

Neurology. 1999 Oct 22;53(7):1495-8.

PMID:
10534257
47.

Thromboxane A2 is a mediator of cyclooxygenase-2-dependent endothelial migration and angiogenesis.

Daniel TO, Liu H, Morrow JD, Crews BC, Marnett LJ.

Cancer Res. 1999 Sep 15;59(18):4574-7.

49.

Covalent modification of cyclooxygenase-2 (COX-2) by 2-acetoxyphenyl alkyl sulfides, a new class of selective COX-2 inactivators.

Kalgutkar AS, Kozak KR, Crews BC, Hochgesang GP Jr, Marnett LJ.

J Med Chem. 1998 Nov 19;41(24):4800-18.

PMID:
9822550
50.

Aspirin-like molecules that covalently inactivate cyclooxygenase-2.

Kalgutkar AS, Crews BC, Rowlinson SW, Garner C, Seibert K, Marnett LJ.

Science. 1998 May 22;280(5367):1268-70.

Supplemental Content

Loading ...
Support Center